Good MorningThe market was largely unmoved by the FOMC on Wednesday after the committee delivered a message that was little more than expected. The FOMC made note of the COVID-vaccines and their impact on the recovery. The committee also noted that labor markets were strengthening although there was still weakness in some areas of the economy. In regards to inflation, committee chairman Jerome Powell says the recent increases in prices are likely to continue although inflation will be transitory.
The after-hours action was a little different. Reports from Facebook, Ford, Ebay, and Apple grabbed the market’s attention and had shares moving. Reports were equally strong and point to an accelerating economic rebound but not all shares moved in the same direction. Action on Thursday could be more of the same sluggish sideways movement as the market digests the latest round of news.
Featured: Trump goes "all-in" on Grand Canyon energy breakthrough (Ad) 
|
Healthcare | |
Shares of BioMarin Pharmaceutical (NASDAQ:BMRN) are trading at light volume as the company prepares to deliver its first quarter 2021 earnings report on April 29, 2021. BRMN stock is down considerably from its 52-week high of $131.94.
It’s always important to understand why a stock moves ... Read the Full Story |
|
From Our Partners | | Palantir, Micron and SanDisk show how fast a stock can become the trade everyone suddenly wants. That's often when investors make their costliest mistake: arriving after the easy part of the move is gone.
A new premium eBook flags 7 stocks that may be worth knowing about before the broader crowd catches on. You don't need to buy any of them - just knowing what's quietly gaining attention can be useful. | | See the 7 stocks on the watchlist while it's still free |
|
Materials | | Large-cap stocks Rio Tinto (NYSE: RIO), Goldman Sachs (NYSE: GS) and PayPal (NASDAQ: PYPL) are all forming potentially constructive price consolidations, and may be nearing buy points.
The old advice to “buy low and sell high” applies to stocks that are consolidating.
But that doesn&... Read the Full Story |
|
Consumer Discretionary | |
A year removed from its historic plunge into the $50's, fast-food restaurant operator Yum! Brands (NYSE:YUM) is approaching its record intraday high of $119.72 set back in August 2018.
The remarkable turnaround is a credit to the company's ability to adapt to the pandemic economy along with marke... Read the Full Story |
|
From Our Partners | | Matt Monaco started with a $2,000 trading account and no clear strategy. After two years of trial and error, he crossed $1 million in 2020.
Today his account sits at $3 million, generating roughly $100,000 a month using a repeatable system he calls The Income Blueprint.
He's revealing the exact five-step scan and three trading lanes behind it in a free live training. | | Reserve your seat and claim The Income Blueprint free |
|
Technology | | One of the biggest pandemic winners last year was Shopify (NYSE:SHOP), a company that offers a software platform for retailers that helps them set up their stores online. The stock rallied over 179% in 2020 thanks to broad shifts in the retail landscape and unprecedented demand for e-commerce. Many ... Read the Full Story |
|
Markets | |
Juniper Networks Is Ready To Bounce Higher
We like Juniper Networks (NYSE: JNPR) for a lot of reasons and think the stock is ready to move higher. Not only is it well-positioned as a networking leader it is gaining relevance in the cloud as well, and it is one of the best dividend-paying stocks ... Read the Full Story |
|
From Our Partners | | Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film.
Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business. | | Watch the full investigation and decide for yourself |
|
Consumer Discretionary | |
Domino’s Pizza (NASDAQ:DPZ) reports first-quarter earnings before the market opens on April 29. Right now, I can understand why some investors may think the thrill is gone. DPZ stock has made an impressive gain of 21% since March 5, 2021. That was after the stock dropped around 14% since the... Read the Full Story |
|
Consumer Discretionary | |
Haverty Furniture Company, What’s Not To Like
We’ve been bullish on the furniture industry and Haverty Furniture Company (NYSE: HVT) for a long time, since well before the pandemic. The trade war with China (remember that?) had the industry on the ropes because it is (or was) so heav... Read the Full Story |
|
Materials | |
Ecolab Fails To Impress With Its Q1 Results
Ecolab (NYSE: ECL) has been one of our top reopening plays since the first of the year and it still is. The company is well-positioned not only as an institutional services company servicing the restaurant, hospitality, and travel industries but also a... Read the Full Story |
|
Finance | |
Like consumers, investors are always after a good bargain. Therefore, many like to seek out undervalued companies with low stock prices. Although a low stock price can have the makings of a 'bear trap', sometimes there are true bargains to be found.
And since corporate insiders are investors like... Read the Full Story |
|
Industrials | | JetBlue Airways (NASDAQ: JBLU) traded lower Tuesday following a better-than-expected first-quarter report.
Shares closed Tuesday at $20.12, down $0.45, or 2.19%.
In its report, the New York-based airline offered a promising glimpse of the current rebound in leisure travel, which could bode well ... Read the Full Story |
|
The Early Bird Stock Of The Day Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. | | View Today's Stock Pick |
|
